🎉 M&A multiples are live!
Check it out!
Company | Headquarters | Sector | Stock Price | Enterprise Value | EV/Revenue | EV/EBITDA |
---|---|---|---|---|---|---|
AstraZeneca | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics | £104 | $242B | 4.2x | 12.2x |
GSK | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics, Vaccines & Immunotherapies | £15 | $98.0B | 2.3x | 6.7x |
Haleon | United Kingdom of Great Britain and Northern Ireland | Health & Beauty, Drug Development & Therapeutics | £4 | $60.8B | 4.0x | 16.0x |
Hikma Pharmaceuticals | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics | £21 | $7.4B | 2.2x | 8.5x |
HUTCHMED | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics | £2 | $1.6B | 2.4x | -66.5x |
Indivior | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics | £9 | $1.5B | 1.3x | 5.2x |
Oxford BioMedica | United Kingdom of Great Britain and Northern Ireland | Contract Research & Manufacturing, Drug Development & Therapeutics | £3 | $524M | 2.7x | -49.3x |
Allergy Therapuetics | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Vaccines & Immunotherapies | £0 | $472M | 6.1x | -19.0x |
Faron Pharmaceuticals | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Vaccines & Immunotherapies | £2 | $370M | 80.5x | -20.7x |
Animalcare Group | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics | £3 | $280M | 2.6x | 14.5x |
4basebio | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Genomics & Personalized Medicine | £11 | $241M | 106.7x | -13.9x |
Avacta Group | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Pharma Diagnostics & Analytics | £0 | $181M | 8.3x | -5.7x |
Scancell | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Vaccines & Immunotherapies | £0 | $141M | N/A | N/A |
MaxCyte | United Kingdom of Great Britain and Northern Ireland | Medical Devices, Drug Development & Therapeutics | £2 | $117M | 2.9x | -3.3x |
PureTech Health | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Biopharmaceuticals | £1 | $95.7M | 3.8x | -0.7x |
Shield Therapeutics | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics | £0 | $54.1M | 1.3x | -3.2x |
Eco Animal Health Group | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics | £1 | $35.8M | 0.3x | 3.6x |
Futura Medical | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics | £0 | $28.7M | 2.1x | -35.4x |
Celadon Pharma | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Cannabis | £0 | $10.6M | N/A | N/A |
Valuation multiples as of last 12 months (LTM). Stock prices as of May 31, 2025. Financial data powered by Morningstar and FactSet.
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.